Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Oncology · Clin Cancer Res · 2026-08-14
Secondary analysis
Borghaei et al. Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung CancerOncology · Ann Oncol · 2026-08-10
RCTn = 970
Kato et al. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648Oncology · Br J Cancer · 2026-07-18
RCTn = 31
Grünwald et al. OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117)Gastroenterology · Lancet Gastroenterol Hepatol · 2026-06-22
RCTn = 229
Merle et al. Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trialOncology · Eur J Cancer · 2026-05-27
Secondary analysisn = 127
Ahrens et al. Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological reviewHaematology · Blood · 2026-04-30
RCTn = 147
Diefenbach et al. A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphomaOncology · Ann Oncol · 2026-03-03
RCTn = 1,096 patients
Choueiri et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trialOncology · J Clin Oncol · 2026-03-03
RCTn = 185 patients
Walter et al. Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II TrialOncology · Lancet Oncol · 2026-03-01
RCTn = 76
van den Hoek et al. Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trialOncology · J Clin Oncol · 2026-02-24
RCT
Scherpereel et al. Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743Oncology · J Thorac Oncol · 2026-02-12
RCTn = 71 patients
Zalcman et al. Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients With Advanced NSCLC: Results of the Randomized IFCT-1701 "DICIPLE" Phase III TrialOncology · Br J Cancer · 2026-02-06
Secondary analysisn = 110
Blanchet et al. Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK studyOncology · J Clin Oncol · 2026-01-07
RCTn = 100
Morris et al. NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal